Results for tag: "Metastatic Prostate Cancer Drug"

The Metastatic Prostate Cancer Drug market is a subset of the larger Prostate Cancer Drugs market. It is composed of drugs used to treat metastatic prostate cancer, which is cancer that has spread beyond the prostate to other parts of the body. These drugs are typically used in combination with other treatments such as surgery, radiation, and hormone therapy. Common drugs used to treat metastatic prostate cancer include abiraterone, enzalutamide, cabazitaxel, and docetaxel. The Metastatic Prostate Cancer Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Pfizer, Astellas Pharma, Sanofi, Merck, and Johnson & Johnson. Other companies include Bristol-Myers Squibb, Bayer, and Novartis. Show Less Read more